PRODUCT
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, Series B funding, neuropsychiatric medicines, Glyph technology platform, biotech investment
FDA Places Clinical Hold on Novavax’s COVID-19-Influenza Combination and Standalone Influenza Vaccine Trials
Novavax, FDA, Clinical Hold, COVID-19, Influenza, Vaccine Trials, Motor Neuropathy
Johnson & Johnson’s Oncology Segment Thrives with Darzalex and Carvykti, Offsetting Stelara Decline
Johnson & Johnson, Darzalex, Carvykti, Stelara, Oncology, Multiple Myeloma, Pharmaceutical Sales
Illumina Introduces MiSeq i100 Series: Simplifying Next-Generation Sequencing with Push-Button Workflows
Illumina, MiSeq i100 Series, Benchtop DNA Sequencer, Push-Button Workflows, Next-Generation Sequencing (NGS), Genomics, DNA Sequencing
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
FDA Panel Recommends Limiting Immunotherapy Access for Stomach and Esophageal Cancer Patients Based on PD-L1 Expression
FDA, Immunotherapy, Stomach Cancer, Esophageal Cancer, PD-L1 Expression, Keytruda, Opdivo, Tevimbra
GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data
GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization
Applied Therapeutics Stock Surges After FDA Cancels Advisory Meeting for Govorestat
Applied Therapeutics, FDA, Govorestat, Advisory Meeting, Classic Galactosemia, Stock Surge
IO Biotech’s IO102-IO103 Vaccine in Combination with Keytruda Shows Promising Results in Phase 2 Trial for Advanced Squamous Cell Carcinoma of the Head and Neck
IO Biotech, IO102-IO103, Keytruda (pembrolizumab), Phase 2 trial, Squamous cell carcinoma of the head and neck (SCCHN), Cancer vaccine, Immunotherapy
ESMO 2024: IO Biotech’s IO102-IO103 Vaccine in Combination with Pembrolizumab Shows Promising Results in Head and Neck Cancer
IO Biotech, IO102-IO103, Pembrolizumab (Keytruda), Head and Neck Cancer, ESMO Congress 2024, Therapeutic Cancer Vaccine, Immunotherapy